87 related articles for article (PubMed ID: 27461248)
1. ADAMTSL5 is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab.
Nonomura Y; Otsuka A; Ohtsuka M; Yamamoto T; Dummer R; Kabashima K
J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):e100-e101. PubMed ID: 27461248
[No Abstract] [Full Text] [Related]
2. Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes.
Fuentes-Duculan J; Bonifacio KM; Hawkes JE; Kunjravia N; Cueto I; Li X; Gonzalez J; Garcet S; Krueger JG
Exp Dermatol; 2017 Nov; 26(11):1075-1082. PubMed ID: 28482118
[TBL] [Abstract][Full Text] [Related]
3. Dramatic Survival Benefit with Nivolumab in Melanoma.
Cancer Discov; 2016 Jun; 6(6):OF7. PubMed ID: 27091855
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab success in untreated metastatic melanoma.
Wilkinson E
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
[No Abstract] [Full Text] [Related]
5. Upregulation of granzyme B and interferon-γ mRNA in responding lesions by treatment with nivolumab for metastatic melanoma: a case report.
Anegawa H; Otsuka A; Kaku Y; Nonomura Y; Fujisawa A; Endo Y; Kabashima K
J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):e231-e232. PubMed ID: 26837059
[No Abstract] [Full Text] [Related]
6. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma.
Kato Y; Otsuka A; Miyachi Y; Kabashima K
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e89-e91. PubMed ID: 26388113
[No Abstract] [Full Text] [Related]
7. Nivolumab: Immunotherapy in Malignant Melanoma.
Bayless H; Schneider S
Clin J Oncol Nurs; 2015 Aug; 19(4):430-2. PubMed ID: 26207707
[TBL] [Abstract][Full Text] [Related]
8. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
Yamazaki N; Maeda Y
Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
[No Abstract] [Full Text] [Related]
9. Nivolumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab (Opdivo) for metastatic melanoma and metastatic NSCLC.
Med Lett Drugs Ther; 2015 Jun; 57(1470):85-7, 94. PubMed ID: 26035747
[No Abstract] [Full Text] [Related]
11. Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.
Matsumura N; Ohtsuka M; Kikuchi N; Yamamoto T
Acta Derm Venereol; 2016 Feb; 96(2):259-60. PubMed ID: 26270860
[No Abstract] [Full Text] [Related]
12. A single-institution study examining cutaneous and non-cutaneous melanomas treated with nivolumab.
Imafuku K; Yoshino K; Ishiwata K; Otobe S; Tsuboi S; Ohara K; Hata H
J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):e227-e229. PubMed ID: 26841210
[No Abstract] [Full Text] [Related]
13. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab provides favorable results in patients with advanced melanoma.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E11. PubMed ID: 25618626
[No Abstract] [Full Text] [Related]
15. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma.
Ohtsuka M; Miura T; Mori T; Ishikawa M; Yamamoto T
JAMA Dermatol; 2015 Jul; 151(7):797-9. PubMed ID: 25875052
[No Abstract] [Full Text] [Related]
17. Severe pneumonitis after nivolumab treatment in a patient with melanoma.
Watanabe S; Kimura H; Takato H; Waseda Y; Hara J; Sone T; Abo M; Maeda S; Matsushita T; Kasahara K
Allergol Int; 2016 Oct; 65(4):487-489. PubMed ID: 27184827
[No Abstract] [Full Text] [Related]
18. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D
Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab: targeting PD-1 to bolster antitumor immunity.
Brahmer JR; Hammers H; Lipson EJ
Future Oncol; 2015; 11(9):1307-26. PubMed ID: 25798726
[TBL] [Abstract][Full Text] [Related]
20. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
